Search Count: 27
 |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.00 Å Release Date: 2023-12-06 Classification: VIRAL PROTEIN Ligands: Y8O |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.60 Å Release Date: 2023-05-17 Classification: HYDROLASE |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.50 Å Release Date: 2023-05-03 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.95 Å Release Date: 2023-05-03 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.11 Å Release Date: 2023-05-03 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.00 Å Release Date: 2023-05-03 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.90 Å Release Date: 2023-05-03 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.30 Å Release Date: 2023-05-03 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.30 Å Release Date: 2023-05-03 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.51 Å Release Date: 2023-04-26 Classification: VIRAL PROTEIN |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:3.00 Å Release Date: 2023-04-26 Classification: VIRAL PROTEIN Ligands: HOH |
 |
Polymorphism In Sars-Cov-2 Nsp5 Main Protease Reveals Differences In Cleavage Of Viral And Host Substrates
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.50 Å Release Date: 2023-04-26 Classification: VIRAL PROTEIN |
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.95 Å Release Date: 2022-12-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTM |
 |
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.15 Å Release Date: 2021-09-01 Classification: VIRAL PROTEIN Ligands: 4IT |
 |
Structure Of Sars-Cov2 3Cl Protease Covalently Bound To Peptidomimetic Inhibitor
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.15 Å Release Date: 2021-07-21 Classification: HYDROLASE/HYDROLASE INHIBITOR Ligands: YWJ, FN7 |
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.90 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTJ |
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.85 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XTP |
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:1.93 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XU4 |
 |
Improved Feline Drugs As Sars-Cov-2 Mpro Inhibitors: Structure-Activity Studies & Micellar Solubilization For Enhanced Bioavailability
Organism: Severe acute respiratory syndrome coronavirus 2
Method: X-RAY DIFFRACTION Resolution:2.00 Å Release Date: 2021-07-07 Classification: VIRAL PROTEIN,HYDROLASE/INHIBITOR Ligands: XV4 |
 |
Covalent Complex Of Sars-Cov Main Protease With N-[(2S)-1-({(2S,3S)-3,4-Dihydroxy-1-[(3S)-2-Oxopyrrolidin-3-Yl]Butan-2-Yl}Amino)-4-Methyl-1-Oxopentan-2-Yl]-4-Methoxy-1H-Indole-2-Carboxamide
Organism: Human sars coronavirus
Method: X-RAY DIFFRACTION Resolution:1.47 Å Release Date: 2020-07-08 Classification: VIRAL PROTEIN Ligands: V2M |